<DOC>
	<DOCNO>NCT01728441</DOCNO>
	<brief_summary>Objective REAL PTX trial compare paclitaxel-eluting stent paclitaxel-eluting balloon treat symptomatic peripheral artery disease femoropopliteal artery .</brief_summary>
	<brief_title>Evaluation Paclitaxel Eluting Stent v Paclitaxel Eluting Balloon Treating Peripheral Artery Disease Femoral Artery</brief_title>
	<detailed_description>The REAL PTX trial design prospective , randomize , multi-center , post-market study investigate effect paclitaxel-eluting stent Zilver® PTX® ( DES ) comparison use paclitaxel elute balloon ( DEB ) treat symptomatic peripheral artery disease femoropopliteal artery . Up 150 patient enrol Germany Belgium . Enrollment expect complete within approximately six month initiate study . One group ( DES DEB ) consider yield significantly well result primary patency rate group 12 month follow .</detailed_description>
	<mesh_term>Peripheral Arterial Disease</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>Subject age ≥ 18 Subject informed nature study , agree participate , sign Medical Ethics Committee approve consent form . Subject understands duration study , agree attend followup visit , agree complete require testing . Rutherford category 25 . Subject de novo restenotic lesion ≥ 70 % stenosis document angiographically prior stent target lesion . Target lesion least 1cm origin profunda femoris exceed medial femoral epicondyle . A single target lesion ( stenotic area separate 3 cm ≤ 30 % stenosis might , decision investigator , consider 2 lesion ) . Reference vessel diameter ( RVD ) ≥ 4 mm ≤ 6.5 mm visual assessment . Patency least one ( 1 ) infrapopliteal artery ankle ( &lt; 50 % diameter stenosis ) continuity native femoropopliteal artery . A guidewire successfully traverse target treatment segment . Clinical exclusion criterion Inability obtain informed consent . Life expectancy &lt; 12 month . Pregnancy , suspect pregnancy , breastfeed study period ( patient childbearing potential must negative serum pregnancy test 7 day prior treatment ) . Presence one follow comorbid factor : hemodialysis dependence , renal insufficiency serum creatinine ≥ 2.5 mg/dl , cerebrovascular accident ( CVA ) within 1 month procedure CVA result unresolved walking impairment , and/or myocardial infarction ( MI ) within 1 month procedure . Any evidence hemodynamic instability prior procedure/randomization . Coagulopathy clot disorder . Present suspect systemic infection osteomyelitis affect target limb . Contraindication contrast medium studyrequired medication ( antiplatelets , anticoagulant , thrombolytic , etc ) . Hypersensitivity nitinol and/or paclitaxel . Enrollment another study . Intervention target lesion le 90 day prior study procedure . Anatomic Untreated external iliac artery inflow lesion ( study allow successful treatment prior study treatment procedure ) . Total occlusion uncrossable conventional guidewire . Acute occlusive intraluminal thrombosis propose lesion site . Evidence aneurysm target lesion site . Perforation target vessel evidence extravasation contrast .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>PAD</keyword>
	<keyword>stenting</keyword>
	<keyword>angioplasty</keyword>
</DOC>